Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
Leadoff Hitter – Spotting High-Risk Players
J.A. Randy Englert, MD, FACC
Swing for the Fences – LDL-C as the Power Hitter
Matthew Malachowski, Pharm. D., MHA
Turning the Double Play – Comprehensive Secondary Prevention
ASCVD Playbook | Closing the Gaps, One Inning at a Time
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD
Ahmad Masri, MD, MS
Michael Nassif, MD, MSc
Molecular Precision: How Myosin Inhibitors Redefine Control
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Ellie Kelepouris, MD, FACP, FAHA